The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.10
Bid: 2.10
Ask: 2.15
Change: -0.05 (-2.30%)
Spread: 0.05 (2.381%)
Open: 2.22
High: 2.22
Low: 2.10
Prev. Close: 2.175
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Apr 2018 08:24

RNS Number : 5795L
Immupharma PLC
20 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Immupharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Lanstead Capital LP

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

17/04/2018

6. Date on which issuer notified (DD/MM/YYYY):

19/04/2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0.00%

0.00%

0.00%

139,467,430

Position of previous notification (if

applicable)

5.01%

0.00%

5.01%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

 

ISIN: GB0033711010

0

0

0.00%

0.00%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

0

0.00%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

N/A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

XLON

Date of completion

17/04/2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDBLBLVZFLBBF
Date   Source Headline
16th Oct 20173:29 pmRNSHolding(s) in Company
4th Oct 20177:00 amRNSCompletion of Lanstead Sharing Agreement
27th Sep 20177:00 amRNSInterim Results
26th Sep 20177:00 amRNSPreparation of Lupuzor'sT Regulatory Submissions
21st Sep 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
19th Sep 20177:00 amRNSNotification of Interim Results
18th Aug 20175:09 pmRNSAIM Rule 17 Notice
12th Jul 201711:00 amRNSGrant of Options
30th Jun 201712:04 pmRNSResult of AGM
30th Jun 20177:00 amRNSUpdate on LupuzorT Pivotal Phase III Study
7th Jun 20177:00 amRNSAnnual Report & Notice of AGM
1st Jun 20177:00 amRNSFinal Results
22nd May 20177:00 amRNSNotification of Full Year Results
17th May 20177:00 amRNSUpdate on Lupuzor Phase III Study
31st Mar 201710:17 amRNSNew Employee Share Option Plan & Grant of Options
31st Mar 20178:33 amRNSNew Employee Share Option Plan & Grant of Options
24th Mar 20177:00 amRNSImmuPharma to present at Master Investor Show
22nd Mar 20178:51 amRNSHolding(s) in Company
20th Mar 201711:41 amRNSHolding(s) in Company
20th Mar 20177:00 amRNSHolding(s) in Company
10th Mar 20173:52 pmRNS£4.1 Million Fund Raise via Accelerated Bookbuild
10th Mar 20177:00 amRNSAccelerated Bookbuild for the Issue of Equity
6th Mar 20173:55 pmRNSHolding(s) in Company
17th Feb 20172:04 pmRNSHolding(s) in Company
25th Jan 20177:00 amRNSUpdate on Lupuzor Phase III Study
24th Jan 20177:00 amRNSChange of Adviser
29th Dec 201610:54 amRNSHolding(s) in Company
22nd Dec 20167:00 amRNSUpdate on Lupuzor Pivotal Phase III Study
16th Nov 20167:00 amRNSUpdate on Cancer Compound IPP-204106 'Nucant'
9th Nov 20167:00 amRNSHolding(s) in Company
26th Oct 20163:42 pmRNSHolding(s) in Company
21st Oct 20165:13 pmRNSClose of Accelerated Bookbuild
21st Oct 20161:33 pmRNSProposed Accelerated Bookbuild for Vendor Placing
30th Sep 20167:00 amRNSHalf-year Report
14th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
7th Sep 20167:00 amRNSUPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
21st Jul 20168:32 amRNSHolding(s) in Company
1st Jul 20163:52 pmRNSHolding(s) in Company
27th Jun 20164:41 pmRNSSecond Price Monitoring Extn
27th Jun 20164:35 pmRNSPrice Monitoring Extension
20th Jun 20167:00 amRNSAppointment of Joint Broker
9th Jun 20165:56 pmRNSHolding(s) in Company
8th Jun 20167:00 amRNSSymposium with Lupuzors Inventor Prof. S Muller
7th Jun 20167:00 amRNSEuropean Patients Commence Dosing in Lupuzor
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM
4th May 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.